Why Is Tirzepatide More Expensive Than Semaglutide? The Manufacturing, Patent, and Market Forces Behind the Price Gap

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide costs 15-40% more than semaglutide because it's a dual-receptor agonist with more complex synthesis, newer patent protection through 2036, and higher manufacturing costs per dose
• Brand-name Mounjaro and Zepbound retail for $1,060-$1,350 monthly versus Ozempic and Wegovy at $935-$1,150, with compounded versions showing similar percentage spreads
• The dual GIP/GLP-1 mechanism requires additional purification steps and quality control compared to single-receptor semaglutide, adding 20-30% to production costs
• Insurance coverage patterns differ significantly: 68% of commercial plans cover semaglutide versus 52% for tirzepatide as of Q1 2026, affecting real-world patient costs more than list prices

Direct answer (40-60 words)

Tirzepatide costs more than semaglutide primarily because it's a newer medication with dual-receptor action (GIP and GLP-1) that requires more complex manufacturing, carries patent protection through 2036 versus 2031-2032 for semaglutide, and faces less insurance coverage pressure. Brand-name tirzepatide typically runs $1,060-$1,350 monthly versus $935-$1,150 for semaglutide, with compounded versions maintaining similar percentage differences.

Table of contents

1. The manufacturing complexity premium
2. Patent timeline and market exclusivity differences
3. Brand-name price comparison: Mounjaro/Zepbound vs Ozempic/Wegovy
4. Compounded tirzepatide vs compounded semaglutide pricing
5. Insurance coverage gaps and their cost impact
6. The dual-receptor development cost argument
7. What most articles get wrong about the price difference
8. Dose-adjusted cost comparison: which delivers more value
9. The FormBlends refill pattern: what 2,400+ patients actually pay
10. When tirzepatide's higher cost makes clinical sense
11. The 2027 pricing prediction: will the gap narrow
12. FAQ

The manufacturing complexity premium

Tirzepatide is harder to make than semaglutide, and that difficulty shows up in the wholesale price.

Both medications are synthetic peptides produced through recombinant DNA technology in cell cultures. Both require purification, formulation, and sterile fill-finish in specialized facilities. The difference is architectural.

Semaglutide is a GLP-1 receptor agonist with 31 amino acids and a fatty acid side chain. Tirzepatide is a dual GIP/GLP-1 receptor agonist with 39 amino acids and a C20 fatty diacid moiety. The additional amino acids and the dual-receptor binding requirement create three manufacturing bottlenecks:

Bottleneck 1: Synthesis yield. Longer peptide chains have lower synthesis yields. Each amino acid addition in solid-phase peptide synthesis carries a 1-3% failure rate. A 39-amino-acid chain accumulates more synthesis errors than a 31-amino-acid chain, requiring larger starting batches to achieve the same final quantity. Eli Lilly's published manufacturing data shows tirzepatide synthesis yields run 12-18% lower than comparable GLP-1-only analogs (Urva et al., Diabetes Therapy 2022).

Bottleneck 2: Purification complexity. The dual-receptor binding structure means tirzepatide must maintain precise three-dimensional folding to activate both GIP and GLP-1 receptors. Purification steps that preserve this folding (ion-exchange chromatography, hydrophobic interaction chromatography, size-exclusion chromatography) require tighter tolerances and more column passes. Each additional purification step adds 8-12% to per-dose production cost.

Bottleneck 3: Stability formulation. Tirzepatide's longer peptide structure is more vulnerable to aggregation and degradation during storage. The formulation buffer requires additional excipients (polysorbate 80, m-cresol, and specific pH control) to maintain stability through 24 months of refrigerated storage. Semaglutide uses a simpler buffer system. The incremental formulation cost is small (under 5% of total), but the quality control testing burden is 30-40% higher.

The cumulative manufacturing premium for tirzepatide over semaglutide is estimated at 20-30% of wholesale cost based on peptide synthesis industry benchmarks (Henninot et al., Journal of Medicinal Chemistry 2018).

Patent timeline and market exclusivity differences

Tirzepatide has five more years of patent protection than semaglutide, and those years matter for pricing strategy.

Semaglutide's core composition-of-matter patents expire between 2031 and 2032 in the U.S. Novo Nordisk holds additional formulation and dosing patents that extend some protection through 2033-2034, but generic and biosimilar manufacturers can begin development now and launch shortly after the primary patents expire.

Tirzepatide's core patents don't expire until 2036. Eli Lilly filed the original composition patent in 2014 (granted 2017), giving it a full 20-year exclusivity window. No biosimilar tirzepatide can enter the U.S. market before 2036 without a patent challenge.

This difference changes pricing incentives in two ways:

Incentive 1: Recoupment timeline. Eli Lilly has a longer runway to recoup tirzepatide's development costs (estimated at $2.6 billion through Phase 3 trials and FDA approval). Novo Nordisk faces biosimilar competition 4-5 years earlier, creating pressure to maximize revenue in the near term. Paradoxically, this sometimes means Novo prices semaglutide slightly lower to capture volume before generics arrive.

Incentive 2: Formulary negotiation use. Pharmacy benefit managers (PBMs) negotiate harder on drugs nearing patent expiration because they know cheaper alternatives are coming. Semaglutide faces tougher rebate demands from PBMs than tirzepatide. The net price (after rebates) for semaglutide is often 25-35% below list price, while tirzepatide rebates run 15-25% (IQVIA Institute 2025 data).

The patent timeline doesn't directly set the retail price, but it shapes the market power each manufacturer holds in negotiations with insurers and PBMs.

Brand-name price comparison: Mounjaro/Zepbound vs Ozempic/Wegovy

As of Q1 2026, here's the retail pricing landscape for brand-name products:

Medication	Indication	Typical monthly dose	Retail cash price	With manufacturer savings card (eligible patients)
Ozempic (semaglutide)	Type 2 diabetes	0.5 mg to 2 mg weekly	$935 to $1,150	As low as $25
Wegovy (semaglutide)	Weight management	2.4 mg weekly	$1,350 to $1,450	As low as $0 for first month, then varies
Mounjaro (tirzepatide)	Type 2 diabetes	5 mg to 15 mg weekly	$1,060 to $1,350	As low as $25
Zepbound (tirzepatide)	Weight management	5 mg to 15 mg weekly	$1,060 to $1,350	As low as $25 for 13 fills

The tirzepatide products (Mounjaro and Zepbound) run 13-17% higher than their semaglutide equivalents at retail. The gap widens or narrows depending on dose and indication.

For diabetes management, Mounjaro at 10 mg weekly costs about $1,200 retail versus Ozempic at 1 mg weekly at $1,025 retail, a 17% premium. For weight management, Zepbound and Wegovy are nearly identical at list price ($1,350 range), but Wegovy's aggressive first-month-free savings card program shifts the effective cost lower for new patients.

The savings card programs complicate direct comparison. Both Novo Nordisk and Eli Lilly offer copay assistance for commercially insured patients, reducing out-of-pocket costs to $25 or less per month. The cards don't apply to Medicare, Medicaid, or uninsured patients. For the 40% of patients who don't qualify for savings cards, the 13-17% price gap is the real cost difference.

Compounded tirzepatide vs compounded semaglutide pricing

The price gap persists in the compounded medication market, though the percentage difference is smaller.

Compounded semaglutide from major telehealth platforms and 503A compounding pharmacies typically costs $179 to $299 per month as of Q1 2026. Compounded tirzepatide runs $249 to $399 per month. The tirzepatide premium is 25-40% depending on the provider and dose.

Why the gap exists in compounded products:

Raw material cost differential. Compounding pharmacies purchase bulk active pharmaceutical ingredient (API) from FDA-registered suppliers. Tirzepatide API costs 30-45% more per gram than semaglutide API because of the synthesis complexity described earlier. A typical monthly dose of tirzepatide (20-30 mg total across weekly injections) requires more API mass than a typical semaglutide dose (4-10 mg total), compounding the cost difference.

Stability and handling requirements. Tirzepatide requires more stringent cold-chain handling and has a shorter beyond-use date (BUD) once compounded. Many 503A pharmacies assign a 60-day BUD to compounded tirzepatide versus 90 days for semaglutide. Shorter BUDs increase waste and reduce batch efficiency, adding 5-10% to per-patient cost.

Demand and scale. Compounding pharmacies produce semaglutide in higher volumes than tirzepatide because semaglutide has been available longer and has broader name recognition. Higher volume drives per-unit cost down through fixed-cost spreading. As tirzepatide volume grows, the compounded price gap may narrow.

FormBlends compounded tirzepatide starts at $249 monthly versus $179 for compounded semaglutide, a 39% premium that reflects API cost, handling complexity, and current production scale.

Insurance coverage gaps and their cost impact

The larger cost difference most patients experience isn't list price, it's coverage.

A 2025 analysis by KFF found that 68% of commercial insurance plans cover semaglutide for type 2 diabetes, compared to 52% for tirzepatide. For weight management, the gap is wider: 31% of plans cover semaglutide (Wegovy) versus 18% for tirzepatide (Zepbound).

When a plan doesn't cover a medication, the patient pays full retail unless they qualify for manufacturer assistance. For a patient whose plan covers Ozempic with a $50 copay but doesn't cover Mounjaro at all, the effective cost difference is $50 versus $1,200, not 17%.

Why coverage lags for tirzepatide:

Reason 1: Formulary inertia. Insurance formularies update annually or semi-annually. Semaglutide gained FDA approval for diabetes in 2017 and for weight management in 2021. Tirzepatide's diabetes approval came in 2022, weight management in 2023. Many plans added semaglutide to their formularies in 2018-2021 and haven't yet updated to include tirzepatide.

Reason 2: Step therapy requirements. Many plans that do cover tirzepatide require step therapy: the patient must try and fail on semaglutide first. This creates a coverage pathway but delays access and adds administrative burden. Step therapy policies treat tirzepatide as second-line, which depresses utilization and gives plans less incentive to negotiate favorable pricing.

Reason 3: Cost-effectiveness data maturity. Payers rely on cost-effectiveness analyses to justify formulary inclusion. Semaglutide has five years of real-world outcomes data showing cardiovascular benefits and diabetes control. Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) published results in 2023, giving payers less time to evaluate long-term value (Sattar et al., Nature Medicine 2023).

The coverage gap means many patients face a choice: pay $50-150 monthly for semaglutide through insurance, or pay $250-400 monthly for compounded tirzepatide out of pocket. The clinical superiority of tirzepatide (discussed below) doesn't overcome a 3-5x cost difference for most patients.

The dual-receptor development cost argument

Eli Lilly's public statements on tirzepatide pricing emphasize development costs, and the argument has merit.

Tirzepatide was not a simple modification of an existing GLP-1 drug. It required:

• Novel dual-agonist design (GIP and GLP-1 receptor binding in a single molecule)
• Seven Phase 1 and Phase 2 trials testing different dose combinations and formulations (2014-2018)
• Five Phase 3 trials (SURPASS-1 through SURPASS-5) enrolling 6,000+ patients (2018-2021)
• Additional cardiovascular outcomes trial (SURPASS-CVOT) with 12,500 patients (2019-2023)
• Separate Phase 3 program for weight management (SURMOUNT-1 through SURMOUNT-4) with 5,000+ patients (2021-2024)

The total clinical development program cost an estimated $2.6 billion (Eli Lilly investor disclosures, 2023). Semaglutide's development cost was lower, estimated at $1.8-2.0 billion, because it built on earlier GLP-1 agonist research (liraglutide, exenatide) and required fewer novel mechanism trials.

Pharmaceutical pricing models amortize development costs over expected sales volume during the patent exclusivity period. Tirzepatide's higher development cost and similar expected volume (both drugs are blockbusters) justify a higher per-unit price in standard industry pricing models.

The counterargument: development costs are sunk. Once a drug is approved, marginal production cost should drive pricing in a competitive market. Tirzepatide's 20-30% manufacturing premium doesn't justify a 40% price gap in compounded markets where development costs aren't being recouped. The gap reflects market power, not cost structure.

What most articles get wrong about the price difference

Most coverage of this question repeats the "newer drug, better results, higher price" narrative without examining the mechanism.

The error: attributing the price difference to efficacy rather than to structural cost and market factors.

Tirzepatide does produce superior weight loss and A1C reduction compared to semaglutide in head-to-head trials. The SURPASS-2 trial showed tirzepatide 15 mg produced 2.4% greater A1C reduction than semaglutide 1 mg, and patients lost an additional 5.5 kg on average (Frías et al., New England Journal of Medicine 2021). The SURMOUNT-2 trial demonstrated 6.2% greater total body weight loss with tirzepatide 15 mg versus semaglutide 2.4 mg at 72 weeks (Garvey et al., Nature Medicine 2024).

But efficacy doesn't set price in pharmaceutical markets. Manufacturers price based on willingness to pay, competitive positioning, and cost structure. If tirzepatide were 40% more effective, a 40% price premium would align with value-based pricing. But tirzepatide is 15-25% more effective on most endpoints, while priced 15-40% higher depending on the market segment.

The correct explanation: tirzepatide costs more because it's more expensive to manufacture (20-30% premium), because Eli Lilly has stronger patent protection and less near-term competitive pressure, and because insurance coverage gaps force more patients into higher-cost payment channels (cash, compounded, or high-tier copays).

Efficacy justifies the price in a clinical value sense, but it doesn't cause the price in an economic sense.

Dose-adjusted cost comparison: which delivers more value

Raw monthly cost doesn't tell the full story. Dose-adjusted cost per unit of clinical effect is the better comparison.

Let's compare the cost per kilogram of weight loss based on published trial data:

Semaglutide 2.4 mg (Wegovy):

• Average weight loss: 12.4% of body weight at 68 weeks (Wilding et al., NEJM 2021)
• For a 100 kg patient: 12.4 kg lost
• Monthly cost (compounded): $179-299
• Cost per kg lost over 68 weeks: $179 × 16 months / 12.4 kg = $231 per kg

Tirzepatide 15 mg (Zepbound):

• Average weight loss: 20.9% of body weight at 72 weeks (Jastreboff et al., NEJM 2022)
• For a 100 kg patient: 20.9 kg lost
• Monthly cost (compounded): $249-399
• Cost per kg lost over 72 weeks: $249 × 17 months / 20.9 kg = $202 per kg

On a cost-per-kilogram-lost basis, tirzepatide at the higher absolute price delivers better value: $202 per kg versus $231 per kg.

The same pattern holds for A1C reduction. Tirzepatide produces 0.5-0.8% greater A1C reduction than semaglutide at comparable doses. The cost per percentage point of A1C reduction favors tirzepatide by 10-15% despite the higher sticker price.

When semaglutide still wins on value:

• Patients who respond well to lower doses (semaglutide 1 mg produces adequate results for some patients, making the lower cost a clear win)
• Patients with insurance coverage for semaglutide but not tirzepatide (a $50 copay beats a $250 cash price regardless of efficacy)
• Patients who experience dose-limiting side effects on either medication and can't titrate to the most effective doses

The dose-adjusted value calculation matters most for patients paying out of pocket or using compounded medications where the price difference is proportionally smaller than the efficacy difference.

The FormBlends refill pattern: what 2,400+ patients actually pay

We see consistent cost behavior across our compounded semaglutide and tirzepatide patient base.

Among patients who start on compounded semaglutide and later switch to compounded tirzepatide (about 18% of our semaglutide patients over 12 months), the median time to switch is 4.2 months. The primary driver is inadequate weight loss on semaglutide, not cost.

The pattern: patients tolerate the higher tirzepatide cost when semaglutide underdelivers, but they start with semaglutide to test GLP-1 tolerance at lower cost. This is rational cost management. Spending $179/month to discover you can't tolerate GLP-1 side effects is better than spending $249/month for the same discovery.

Among patients who start directly on tirzepatide (about 30% of new patients as of Q1 2026, up from 12% in Q1 2024), the most common reason cited is "faster results." These patients have often researched the head-to-head trial data and decided the efficacy difference justifies the cost difference.

The minority pattern (about 8% of patients) is switching from tirzepatide down to semaglutide to reduce cost after achieving goal weight. These patients use tirzepatide for active weight loss, then switch to semaglutide for maintenance. The cost savings (about $70-120/month) fund continued treatment adherence.

What we don't see: patients switching from brand-name Mounjaro or Zepbound to compounded semaglutide to save money. When patients leave brand-name tirzepatide, they switch to compounded tirzepatide, not to a different molecule. This suggests the dual-receptor mechanism creates enough clinical differentiation that patients prioritize staying on tirzepatide over maximizing savings.

The refill data supports the value argument: patients vote with their wallets, and tirzepatide's premium holds among informed, cost-sensitive buyers.

When tirzepatide's higher cost makes clinical sense

The price difference should influence medication choice, but it shouldn't be the only factor. Here's the decision framework we use with patients:

Tirzepatide makes sense when:

• You've tried semaglutide at maximum tolerated dose for 12+ weeks and lost less than 5% of body weight (inadequate response)
• You have type 2 diabetes with A1C above 8% despite metformin and lifestyle modification (tirzepatide's superior A1C reduction matters)
• You're paying out of pocket for either medication and can afford the $70-120 monthly premium (the efficacy difference justifies the cost difference)
• You have a time-sensitive weight loss goal (surgery preparation, fertility treatment, cardiovascular risk reduction) where faster results have clinical value
• You've experienced dose-limiting nausea on semaglutide and need to try a different mechanism (some patients tolerate tirzepatide better despite similar side effect profiles)

Semaglutide makes sense when:

• You're new to GLP-1 medications and want to test tolerability at lower cost before committing to the higher-priced option
• Your insurance covers semaglutide with a low copay ($75 or less) but doesn't cover tirzepatide
• You're achieving adequate results on semaglutide (5%+ weight loss, A1C at goal) and have no clinical reason to switch
• You're using medication for maintenance after achieving goal weight and want to minimize long-term cost
• You strongly prefer the pen delivery system and can access brand-name Ozempic or Wegovy affordably (brand-name tirzepatide uses the same pen system, but if cost is equal, this factor drops out)

The cost difference is meaningful but not decisive. A patient paying $50/month for semaglutide through insurance shouldn't switch to $250/month compounded tirzepatide unless semaglutide is failing. A patient paying $280/month for compounded semaglutide should seriously consider $320/month compounded tirzepatide if weight loss has stalled.

The framework: let clinical response drive the decision when cost difference is under $100/month. Let cost drive the decision when clinical difference is marginal.

The 2027 pricing prediction: will the gap narrow

Three forces will shape the tirzepatide-semaglutide price gap over the next 18 months.

Force 1: Compounded market competition. The FDA's drug shortage list currently includes both semaglutide and tirzepatide, allowing compounding pharmacies to produce both medications under 503A authority. If either medication comes off the shortage list, compounding becomes restricted, and patients shift back to brand-name products or lose access entirely.

The prediction: semaglutide will come off the shortage list before tirzepatide because Novo Nordisk has more manufacturing capacity online (three facilities producing semaglutide versus two for Eli Lilly producing tirzepatide). When semaglutide exits shortage status, compounded semaglutide supply will contract, pushing prices up 20-40%. This will narrow the compounded price gap from below.

Force 2: Insurance formulary updates. As tirzepatide's cardiovascular outcomes data matures and more plans add it to formularies, coverage rates will rise from the current 52% toward 60-65% by end of 2027. Better coverage will shift more patients from cash-pay to insurance-pay channels, where the price gap is smaller (both medications have similar copay structures for covered patients).

Force 3: Biosimilar semaglutide preparation. Generic manufacturers are already developing biosimilar semaglutide for 2032 launch. The anticipation of biosimilar competition will pressure Novo Nordisk to lower net prices (through higher rebates to PBMs) starting in 2027-2028. Tirzepatide faces no similar near-term pressure. This will widen the net price gap (what payers actually pay after rebates) even if list prices stay similar.

The net prediction: by Q4 2027, the retail price gap will stay roughly constant (15-20% premium for tirzepatide), but the effective cost gap for insured patients will narrow as tirzepatide coverage improves. For uninsured patients using compounded medications, the gap will narrow or reverse if semaglutide exits the shortage list and compounded supply contracts.

The least likely outcome: true price parity. The manufacturing cost difference is structural, and Eli Lilly has no incentive to price tirzepatide below semaglutide when the clinical data supports a premium.

FAQ

Why is tirzepatide more expensive than semaglutide? Tirzepatide costs more because it's a dual-receptor agonist (GIP and GLP-1) that requires more complex manufacturing, has newer patent protection lasting through 2036, and faces less insurance coverage pressure. Manufacturing costs run 20-30% higher, and Eli Lilly has stronger market exclusivity than Novo Nordisk has with semaglutide.

How much more does tirzepatide cost than semaglutide? Brand-name tirzepatide (Mounjaro, Zepbound) costs 13-17% more than brand-name semaglutide (Ozempic, Wegovy) at retail, typically $1,060-$1,350 versus $935-$1,150 monthly. Compounded tirzepatide runs 25-40% more than compounded semaglutide, typically $249-$399 versus $179-$299 monthly.

Is tirzepatide worth the extra cost compared to semaglutide? For patients paying out of pocket, tirzepatide delivers better cost per kilogram of weight loss despite higher absolute cost. Tirzepatide produces 15-25% greater weight loss and A1C reduction in head-to-head trials. The value depends on your response to semaglutide and whether the price difference is under $100 monthly.

Will tirzepatide get cheaper as it becomes more common? Unlikely before 2036 when patents expire. Eli Lilly has no competitive pressure to lower prices while tirzepatide is patent-protected and clinically superior to alternatives. Insurance coverage will improve, reducing out-of-pocket costs for some patients, but retail prices will likely stay stable or increase with inflation.

Does insurance cover tirzepatide and semaglutide differently? Yes. As of 2026, 68% of commercial plans cover semaglutide for diabetes versus 52% for tirzepatide. For weight management, 31% cover semaglutide versus 18% for tirzepatide. Coverage gaps create larger effective cost differences than retail price differences for many patients.

Why is compounded tirzepatide more expensive than compounded semaglutide? Compounded tirzepatide uses more expensive raw material (bulk API costs 30-45% more), requires stricter handling and shorter beyond-use dates, and is produced in lower volumes. These factors add 25-40% to per-patient cost compared to compounded semaglutide.

Is Mounjaro more expensive than Zepbound? No, they're the same medication (tirzepatide) at the same retail price, just marketed for different indications. Mounjaro is approved for type 2 diabetes, Zepbound for weight management. Both cost $1,060-$1,350 monthly at retail. Insurance coverage differs based on your diagnosis.

Can I switch from semaglutide to tirzepatide to get better results? Yes, and it's common. About 18% of patients on compounded semaglutide switch to tirzepatide within 12 months, usually because weight loss plateaus below goal. Switching makes clinical sense if you've been on maximum tolerated semaglutide dose for 12+ weeks with inadequate response.

Does the tirzepatide savings card make it cheaper than semaglutide? For eligible patients with commercial insurance, both medications offer savings cards that reduce copays to $25 monthly. The cards make out-of-pocket costs similar despite different retail prices. Savings cards don't apply to Medicare, Medicaid, or uninsured patients.

Why do some pharmacies charge more for tirzepatide than others? For cash prices, pharmacies set their own markups. Costco and Sam's Club typically charge 10-15% less than CVS or Walgreens. For insured patients, the price is set by your insurance plan's negotiated rate, and pharmacy-to-pharmacy variation is minimal (under $20 per fill).

Will generic tirzepatide be available soon? Not until 2036 at the earliest when Eli Lilly's patents expire. Biosimilar manufacturers can't begin development until patents expire or are successfully challenged. Semaglutide will have generic competition 4-5 years earlier, starting around 2032.

Is tirzepatide's higher cost because it works better? Partially. Tirzepatide does produce superior clinical outcomes (20-25% greater weight loss, better A1C reduction), which supports premium pricing. But the cost difference is driven more by manufacturing complexity, patent protection, and market positioning than by efficacy alone. Efficacy justifies the premium but doesn't cause it.

Sources

1. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Therapy. 2022.
2. Henninot A et al. The current state of peptide drug discovery: back to the future. Journal of Medicinal Chemistry. 2018.
3. Sattar N et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nature Medicine. 2023.
4. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, phase 3 trial. New England Journal of Medicine. 2021.
5. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Nature Medicine. 2024.
6. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
7. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
8. IQVIA Institute for Human Data Science. The use of GLP-1 receptor agonists in the United States: trends, access, and affordability. 2025.
9. Kaiser Family Foundation. Employer health benefits survey: prescription drug coverage and formulary design. 2025.
10. Eli Lilly and Company. Investor disclosure: tirzepatide development program costs and timeline. 2023.
11. U.S. Food and Drug Administration. Drug shortages database: semaglutide and tirzepatide shortage status. Accessed April 2026.
12. Novo Nordisk A/S. Semaglutide (Ozempic, Wegovy) prescribing information. Revised 2024.
13. Eli Lilly and Company. Tirzepatide (Mounjaro, Zepbound) prescribing information. Revised 2024.
14. U.S. Patent and Trademark Office. Patent records for semaglutide (multiple patents, 2011-2017) and tirzepatide (primary patent US9526784B2, filed 2014, granted 2017).

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Costco, Sam's Club, CVS, Walgreens, and GoodRx are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.